Biogen Idec Inc. — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing; it also reports fourth-quarter results. Unless noted, amounts are U.S. dollars.
Business context
Biogen Idec was a global biopharmaceutical company focused on neurological, autoimmune and hematologic disorders. Its principal businesses included multiple sclerosis (MS) therapies, the newly launched hemophilia products ALPROLIX and ELOCTATE, and collaboration revenues from RITUXAN and GAZYVA. The company identified continued sales of key products—especially TECFIDERA—as central to near-term performance.
Financial performance and liquidity
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $9.703 billion | $6.932 billion | +40.0% |
| Operating income | $3.972 billion | $2.516 billion | +57.9% |
| Net income attributable to Biogen Idec | $2.935 billion | $1.862 billion | +57.6% |
| Diluted EPS | $12.37 | $7.81 | +58.3% |
| Operating cash flow | $2.942 billion | $2.345 billion | +25.5% |
Operating margin was approximately 40.9% and net margin approximately 30.3% in 2014, calculated from reported annual figures. Gross profit, as defined in the quarterly table (revenue less cost of sales excluding acquired-intangible amortization), was $8.532 billion, or approximately 87.9% of revenue.
- Revenue mix: Product revenue was $8.203 billion (+48.0%); unconsolidated joint business revenue was $1.195 billion (+6.2%); other revenue was $304.5 million (+15.4%). U.S. product revenue grew 55.5%, while rest-of-world product revenue grew 34.4%.
- Key products: TECFIDERA generated $2.909 billion (+232.1%); TYSABRI $1.960 billion (+28.4%); AVONEX $3.013 billion (+0.3%). PLEGRIDY generated $44.5 million, ALPROLIX $76.0 million and ELOCTATE $58.4 million in their initial commercial year.
- Expenses: Total costs and expenses rose 29.4% to $5.748 billion. R&D increased 31.1% to $1.893 billion; selling, general and administrative expense rose 30.4% to $2.232 billion; acquired-intangible amortization rose 42.8% to $489.8 million.
- Quarterly context: Fourth-quarter revenue was $2.641 billion and net income attributable to Biogen Idec was $883.5 million, versus $1.966 billion and $457.3 million, respectively, in Q4 2013. Q4 diluted EPS was $3.74 versus $1.92.
- Balance sheet: Cash, cash equivalents and marketable securities totaled $3.316 billion at year-end, up from $1.849 billion. Working capital was $2.453 billion, compared with $1.427 billion. Total borrowings were $585.2 million; shareholders’ equity was $10.809 billion.
- Cash uses: Investing activities used $1.543 billion, including $375.0 million in Fumapharm contingent payments and $287.8 million in capital spending. Financing activities used $755.9 million, including $886.8 million for share repurchases. No cash dividend was paid.
Material changes versus 2013
- TECFIDERA’s rapid commercial expansion was a major growth driver; its 2014 revenue included a full year of sales compared with its U.S. launch in April 2013. Germany sales began in 2014.
- Biogen began commercializing PLEGRIDY, ALPROLIX and ELOCTATE after regulatory approvals in 2014. TYSABRI revenue also benefited from full-year ownership following the 2013 acquisition of remaining rights from Elan.
- AVONEX revenue was nearly flat. U.S. unit sales fell 10%, and European demand declined, in part as patients moved to oral MS treatments, including TECFIDERA.
- R&D and commercial spending increased with pipeline investment and product launches. The company recorded a $38.9 million gain from remeasurement of contingent consideration, compared with a $0.5 million gain in 2013.
- Operating cash flow improved, but working-capital demands increased, notably from higher receivables and inventory. Year-end cash and securities rose partly because operating cash generation more than offset repurchases and other uses.
Outlook, commentary, risks and unusual items
- Management expected rest-of-world TECFIDERA revenue to increase as the product became available in additional markets in 2015. No clear overall 2015 revenue or earnings guidance is provided in the filing.
- The company estimated royalty revenue would decline by approximately $130 million in 2015, largely because ANGIOMAX royalties ceased when the relevant patent expired on December 15, 2014.
- Management planned significant ongoing R&D investment. Pipeline priorities included ZINBRYTA, spinal muscular atrophy candidate ISIS-SMN Rx, Alzheimer’s programs and hemophilia products; development and regulatory outcomes remain uncertain.
- Material unusual items included a $43.6 million incremental branded pharmaceutical drug fee recognized in 2014 for 2013 and 2014 periods; $50.9 million of intangible-asset impairment charges; and $375.0 million of cash contingent payments to former Fumapharm owners, with a further $250.0 million accrued at year-end.
- Risks include dependence on a concentrated group of products and MS revenues; competition, including generics and biosimilars; safety issues (including PML warnings for TYSABRI and TECFIDERA); pricing and reimbursement pressure; patent disputes; clinical and regulatory setbacks; and manufacturing or third-party supply disruptions.
- Additional exposures include delayed government payments in parts of Europe, foreign-exchange volatility, tax disputes and uncertain tax positions. The Danish tax authority assessed $51.1 million, including interest, for 2009; the company contests the assessment. Government investigations into sales and promotional practices and pharmacy-benefit-manager relationships were ongoing.
- Potential collaboration and licensing milestone payments totaled up to approximately $2.8 billion, contingent on achievement. The company stated existing funds and operating cash flows should be sufficient for foreseeable needs. Approximately $1.755 billion of year-end cash and securities was generated outside the U.S. and primarily intended for foreign operations; repatriation could create significant tax expense.
Important facts for investors to verify
- Whether TECFIDERA growth in new markets can offset competition and declines or patient transitions affecting AVONEX and other MS products.
- Launch uptake, pricing, reimbursement, safety profile and contribution margins for PLEGRIDY, ALPROLIX and ELOCTATE.
- Progress, regulatory timing and commercial potential of major pipeline programs, particularly ZINBRYTA, ISIS-SMN Rx and Alzheimer’s candidates.
- Exposure to TYSABRI contingent payments to Elan, Fumapharm sales-based payments, and the timing and attainability of other milestones.
- Resolution and potential financial effects of the AIFA TYSABRI matter, patent litigation, government investigations and tax disputes.
- Whether European receivables remain collectible on expected timelines, and how currency movements and the anticipated ANGIOMAX royalty decline affect results.